Control of eosinophil toxicity in the lung

Garry Michael Walsh, M. Al-Rabia, Morgan G Blaylock, D W Sexton, C. J. Duncan, A Lawrie

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The inappropriate accumulation of eosinophils and the subsequent release of their potent pro-inflammatory mediator arsenal are thought to be important contributors to the pathogenesis of asthma and other allergic diseases. It is also becoming apparent that eosinophils may play a role in the orchestration of immune responses in the asthmatic lung. There is therefore much interest in the development of strategies to limit or prevent eosinophil-induced toxicity. The mechanisms by which eosinophils accumulate in the peribronchial tissues of the lung are complex and include enhanced differentiation and release from the bone marrow, selective adhesion and transendothelial migration, directed movement in response to specific chemotactic mediators and finally prolonged survival as a consequence of delayed apoptosis. Thus it can be appreciated that there are many points at which the toxicity of eosinophils can be limited or even prevented. Important areas for potential advances in glucocorticoid (GC) development include efforts to dissociate their anti-inflammatory effects from unwanted side effects. Other areas include the development of humanized monoclonal antibodies against IL-4, IL-13 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for eosinophil accumulation in the asthmatic lung. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. This review will discuss both the potential and shortcomings of these diverse approaches to limit eosinophil toxicity in the asthmatic lung.
Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalCurrent Drug Targets. Inflammation and Allergy
Volume4
Issue number4
DOIs
Publication statusPublished - 1 Aug 2005

Fingerprint

Eosinophils
Lung
Apoptosis
Transendothelial and Transepithelial Migration
Antibodies, Monoclonal, Humanized
Interleukin-13
Interleukin-5
Phagocytes
Chemokines
Interleukin-4
Glucocorticoids
Anti-Inflammatory Agents
Asthma
Eating
Bone Marrow
Research

Keywords

  • animals
  • anti-asthmatic agents
  • apoptosis
  • asthma
  • cell adhesion molecules
  • chemokine CCL11
  • chemokines, CC
  • eosinophils
  • humans
  • lung
  • phagocytosis

Cite this

Walsh, G. M., Al-Rabia, M., Blaylock, M. G., Sexton, D. W., Duncan, C. J., & Lawrie, A. (2005). Control of eosinophil toxicity in the lung. Current Drug Targets. Inflammation and Allergy, 4(4), 481-486. https://doi.org/10.2174/1568010054526296

Control of eosinophil toxicity in the lung. / Walsh, Garry Michael; Al-Rabia, M.; Blaylock, Morgan G; Sexton, D W ; Duncan, C. J.; Lawrie, A.

In: Current Drug Targets. Inflammation and Allergy, Vol. 4, No. 4, 01.08.2005, p. 481-486.

Research output: Contribution to journalArticle

Walsh, GM, Al-Rabia, M, Blaylock, MG, Sexton, DW, Duncan, CJ & Lawrie, A 2005, 'Control of eosinophil toxicity in the lung', Current Drug Targets. Inflammation and Allergy, vol. 4, no. 4, pp. 481-486. https://doi.org/10.2174/1568010054526296
Walsh, Garry Michael ; Al-Rabia, M. ; Blaylock, Morgan G ; Sexton, D W ; Duncan, C. J. ; Lawrie, A. / Control of eosinophil toxicity in the lung. In: Current Drug Targets. Inflammation and Allergy. 2005 ; Vol. 4, No. 4. pp. 481-486.
@article{755a41f836b34a81b3152e179f53320c,
title = "Control of eosinophil toxicity in the lung",
abstract = "The inappropriate accumulation of eosinophils and the subsequent release of their potent pro-inflammatory mediator arsenal are thought to be important contributors to the pathogenesis of asthma and other allergic diseases. It is also becoming apparent that eosinophils may play a role in the orchestration of immune responses in the asthmatic lung. There is therefore much interest in the development of strategies to limit or prevent eosinophil-induced toxicity. The mechanisms by which eosinophils accumulate in the peribronchial tissues of the lung are complex and include enhanced differentiation and release from the bone marrow, selective adhesion and transendothelial migration, directed movement in response to specific chemotactic mediators and finally prolonged survival as a consequence of delayed apoptosis. Thus it can be appreciated that there are many points at which the toxicity of eosinophils can be limited or even prevented. Important areas for potential advances in glucocorticoid (GC) development include efforts to dissociate their anti-inflammatory effects from unwanted side effects. Other areas include the development of humanized monoclonal antibodies against IL-4, IL-13 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for eosinophil accumulation in the asthmatic lung. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. This review will discuss both the potential and shortcomings of these diverse approaches to limit eosinophil toxicity in the asthmatic lung.",
keywords = "animals, anti-asthmatic agents, apoptosis, asthma, cell adhesion molecules, chemokine CCL11, chemokines, CC, eosinophils, humans, lung, phagocytosis",
author = "Walsh, {Garry Michael} and M. Al-Rabia and Blaylock, {Morgan G} and Sexton, {D W} and Duncan, {C. J.} and A Lawrie",
year = "2005",
month = "8",
day = "1",
doi = "10.2174/1568010054526296",
language = "English",
volume = "4",
pages = "481--486",
journal = "Current Drug Targets. Inflammation and Allergy",
issn = "1568-010X",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Control of eosinophil toxicity in the lung

AU - Walsh, Garry Michael

AU - Al-Rabia, M.

AU - Blaylock, Morgan G

AU - Sexton, D W

AU - Duncan, C. J.

AU - Lawrie, A

PY - 2005/8/1

Y1 - 2005/8/1

N2 - The inappropriate accumulation of eosinophils and the subsequent release of their potent pro-inflammatory mediator arsenal are thought to be important contributors to the pathogenesis of asthma and other allergic diseases. It is also becoming apparent that eosinophils may play a role in the orchestration of immune responses in the asthmatic lung. There is therefore much interest in the development of strategies to limit or prevent eosinophil-induced toxicity. The mechanisms by which eosinophils accumulate in the peribronchial tissues of the lung are complex and include enhanced differentiation and release from the bone marrow, selective adhesion and transendothelial migration, directed movement in response to specific chemotactic mediators and finally prolonged survival as a consequence of delayed apoptosis. Thus it can be appreciated that there are many points at which the toxicity of eosinophils can be limited or even prevented. Important areas for potential advances in glucocorticoid (GC) development include efforts to dissociate their anti-inflammatory effects from unwanted side effects. Other areas include the development of humanized monoclonal antibodies against IL-4, IL-13 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for eosinophil accumulation in the asthmatic lung. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. This review will discuss both the potential and shortcomings of these diverse approaches to limit eosinophil toxicity in the asthmatic lung.

AB - The inappropriate accumulation of eosinophils and the subsequent release of their potent pro-inflammatory mediator arsenal are thought to be important contributors to the pathogenesis of asthma and other allergic diseases. It is also becoming apparent that eosinophils may play a role in the orchestration of immune responses in the asthmatic lung. There is therefore much interest in the development of strategies to limit or prevent eosinophil-induced toxicity. The mechanisms by which eosinophils accumulate in the peribronchial tissues of the lung are complex and include enhanced differentiation and release from the bone marrow, selective adhesion and transendothelial migration, directed movement in response to specific chemotactic mediators and finally prolonged survival as a consequence of delayed apoptosis. Thus it can be appreciated that there are many points at which the toxicity of eosinophils can be limited or even prevented. Important areas for potential advances in glucocorticoid (GC) development include efforts to dissociate their anti-inflammatory effects from unwanted side effects. Other areas include the development of humanized monoclonal antibodies against IL-4, IL-13 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for eosinophil accumulation in the asthmatic lung. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. This review will discuss both the potential and shortcomings of these diverse approaches to limit eosinophil toxicity in the asthmatic lung.

KW - animals

KW - anti-asthmatic agents

KW - apoptosis

KW - asthma

KW - cell adhesion molecules

KW - chemokine CCL11

KW - chemokines, CC

KW - eosinophils

KW - humans

KW - lung

KW - phagocytosis

U2 - 10.2174/1568010054526296

DO - 10.2174/1568010054526296

M3 - Article

VL - 4

SP - 481

EP - 486

JO - Current Drug Targets. Inflammation and Allergy

JF - Current Drug Targets. Inflammation and Allergy

SN - 1568-010X

IS - 4

ER -